文献速递乳腺癌泌尿男性生殖肿瘤消化系统肿瘤

男性BRCA1、BRCA2及相关癌症风险与管理:综述

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.
PubMed 文献 · JAMA Oncol · 2024-01-01

本文为叙述性综述,汇总男性BRCA1/2致病性变异携带者的癌症风险、靶向治疗选择与早期检测指南,并指出已有证据显示男性携带者前列腺癌、胰腺癌和乳腺癌风险增加。尽管临床可干预性提高,接受基因检测的男性仍远少于女性,作者呼吁肿瘤科、内科和初级保健医生积极为男性提供适当基因检测。

要点

  • 男性携带BRCA1/2致病性变异与前列腺癌、胰腺癌和乳腺癌风险增加相关。
  • FDA已批准多种靶向药物(含PARP抑制剂)用于BRCA1/2相关乳腺癌、胰腺癌和前列腺癌。
  • 男性接受癌症基因检测的比例远低于女性,肿瘤科、内科和初级保健医生应积极提供检测。

核心结论

  • 男性BRCA1/2致病性变异携带者的临床可干预性不断增加,但接受癌症基因检测的男性远少于女性。
  • 肿瘤科、内科和初级保健医生应积极为男性提供适当的基因检测。
  • 识别更多男性携带者有助于最大化癌症早期检测、靶向风险管理和治疗机会,并促进家系成员的风险降低与预防。

研究设计与样本

  • 叙述性综述,汇总男性BRCA1/2致病性变异携带者的癌症风险、靶向治疗选择和早期癌症检测指南数据,并指出新兴研究方向与临床试验机会。

主要发现

  • 有令人信服的证据表明男性BRCA1/2致病性变异携带者前列腺癌、胰腺癌和乳腺癌风险增加。
  • 美国食品药品监督管理局批准的靶向治疗(包括PARP抑制剂)快速扩展,用于BRCA1/2致病性变异相关的乳腺癌、胰腺癌和前列腺癌。
  • 上述进展及对家族癌症风险和生育选择的持续相关性,已促使基因检测指南推荐发生变化,并加强了增加男性基因检测的理由。

临床怎么用

  • 肿瘤科、内科和初级保健医生应积极为男性提供适当的基因检测。
  • 识别更多男性BRCA1/2致病性变异携带者有助于最大化癌症早期检测、靶向风险管理和癌症治疗机会,并促进家系成员的风险降低与预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in female carriers, and knowledge of BRCA1/2 PVs informs established cancer screening and options for risk reduction. While risks to male carriers of BRCA1/2 PVs are less characterized, there is convincing evidence of increased risk for prostate cancer, pancreatic cancer, and breast cancer in males. There has also been a rapid expansion of US Food and Drug Administration-approved targeted cancer therapies, including poly ADP ribose polymerase (PARP) inhibitors, for breast, pancreatic, and prostate cancers associated with BRCA1/2 PVs. OBSERVATIONS: This narrative review summarized the data that inform cancer risks, targeted cancer therapy options, and guidelines for early cancer detection. It also highlighted areas of emerging research and clinical trial opportunities for male BRCA1/2 PV carriers. These developments, along with the continued relevance to family cancer risk and reproductive options, have informed changes to guideline recommendations for genetic testing and strengthened the case for increased genetic testing for males. CONCLUSIONS AND RELEVANCE: Despite increasing clinical actionability for male carriers of BRCA1/2 PVs, far fewer males than female individuals undergo cancer genetic testing. Oncologists, internists, and primary care clinicians should be vigilant about offering appropriate genetic testing to males. Identifying more male carriers of BRCA1/2 PVs will maximize opportunities for cancer early detection, targeted risk management, and cancer treatment for males, along with facilitating opportunities for risk reduction and prevention in their family members, thereby decreasing the burden of hereditary cancer.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Cheng HH, Shevach JW, Castro E, et al. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review. JAMA Oncol. 2024. PMID: 39052257. doi:10.1001/jamaoncol.2024.2185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。